Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 14/20 | 1.00 |
| ▸ | XDH | P47989 | 7/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | FEN1 | P39748 | 1/20 | 0.54 |
| ▸ | CA12 | O43570 | 2/20 | 0.53 |
| ▸ | CA1 | P00915 | 2/20 | 0.53 |
| ▸ | CA2 | P00918 | 2/20 | 0.53 |
| ▸ | CA9 | Q16790 | 1/20 | 0.53 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | PRNP | P04156 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2732033 | 0.77 | MPO (1.00) | MPOXDHMEN1KMT2AFEN1 | |
| SCHEMBL2731084 | 0.76 | ALDH1A1 (0.68) | MPOXDHMEN1KMT2A | |
| SCHEMBL23045531 | 0.76 | ALDH1A1 (0.71) | MPOXDHMEN1KMT2ACA12 | |
| SCHEMBL15215601 | 0.73 | MPO (0.66) | MPOXDHCA12CA1CA2 | |
| SCHEMBL26655711 | 0.73 | MPO (0.57) | MPOXDHMEN1KMT2AFEN1 | |
| SCHEMBL26655709 | 0.73 | MPO (0.57) | MPOXDHMEN1KMT2AFEN1 | |
| SCHEMBL29446368 | 0.73 | MPO (0.57) | MPOXDHMEN1KMT2AFEN1 | |
| SCHEMBL26655708 | 0.73 | MPO (0.67) | MPOXDHMEN1KMT2ACA12 | |
| SCHEMBL6214704 | 0.72 | MPO (0.56) | MPOXDHMEN1KMT2ACA12 | |
| SCHEMBL30103280 | 0.72 | CA12 (0.57) | MPOXDHMEN1KMT2AFEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160243121-A1 | Quinazoline Derivatives, Compositions, and Uses Related Thereto | UNIV EMORY (US) | 2016-08-25 | — | — | US | claimed |
| US-20150110723-A1 | QUINAZOLINE DERIVATIVES, COMPOSITIONS, AND USES RELATED THERETO | EMORY UNIVERSITY (US) | 2015-04-23 | — | — | US | claimed |
| WO-2013181135-A1 | QUINAZOLINE DERIVATIVES, COMPOSITIONS, AND USES RELATED THERETO | EMORY UNIVERSITY (US) | 2013-12-05 | — | — | WO | claimed |
| US-20160243121-A1 | Quinazoline Derivatives, Compositions, and Uses Related Thereto | UNIV EMORY (US) | 2016-08-25 | — | — | US | disclosed |
| US-20160243121-A1 | Quinazoline Derivatives, Compositions, and Uses Related Thereto | UNIV EMORY (US) | 2016-08-25 | — | — | US | disclosed |
| US-20150110723-A1 | QUINAZOLINE DERIVATIVES, COMPOSITIONS, AND USES RELATED THERETO | EMORY UNIVERSITY (US) | 2015-04-23 | — | — | US | disclosed |
| US-20150110723-A1 | QUINAZOLINE DERIVATIVES, COMPOSITIONS, AND USES RELATED THERETO | EMORY UNIVERSITY (US) | 2015-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160243121-A1 | Quinazoline Derivatives, Compositions, and Uses Related Thereto | NOX3, NOX1, NOX5 | MPO 6/4885XDH 10/4885MEN1 4758/4885 |
| US-20150110723-A1 | QUINAZOLINE DERIVATIVES, COMPOSITIONS, AND USES RELATED THERETO | NOX3, NOX1, NOX5 | MPO 6/4885XDH 10/4885MEN1 4758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.